Akari Therapeutics, Plc (AKTX)

Akari Therapeutics, Analyst Ratings

AKTX's stock price has decreased by -74.38% in the past year and price targets may not have had time to catch up.

• Total Analysts: 2
• Consensus Rating: Strong Buy
• Price Target: $3.30
• Upside: +1,169.23%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Sean Lee HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $1.6	Strong Buy	Reiterates	$1.6	+515.38%	Sep 9, 2025
Jason McCarthy Maxim Group	Maxim Group	Strong Buy Initiates $5	Strong Buy	Initiates	$5	+1,823.08%	Jul 18, 2025
Sean Lee HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $30	Strong Buy	Initiates	$30	+11,438.46%	Dec 5, 2022
James Molloy Alliance Global Partners	Alliance Global Partners	Strong Buy Initiates $80	Strong Buy	Initiates	$80	+30,669.23%	Nov 1, 2022
Madhu Kumar B. Riley Securities	B. Riley Securities	Strong Buy Maintains $140 → $100	Strong Buy	Maintains	$140 → $100	+38,361.54%	Mar 13, 2020
Arlinda Lee Canaccord Genuity	Canaccord Genuity	Strong Buy Maintains $300 → $160	Strong Buy	Maintains	$300 → $160	+61,438.46%	Mar 29, 2018
Madhu Kumar B. Riley Securities	B. Riley Securities	Hold Initiates $60	Hold	Initiates	$60	+22,976.92%	Feb 8, 2018
Tim Lugo William Blair	William Blair	Hold → Buy Upgrades n/a	Hold → Buy	Upgrades	n/a	n/a	Sep 22, 2017
Madhu Kumar Chardan Capital	Chardan Capital	Strong Sell → Hold Upgrades n/a	Strong Sell → Hold	Upgrades	n/a	n/a	May 31, 2017
Tim Lugo William Blair	William Blair	Buy → Hold Downgrades n/a	Buy → Hold	Downgrades	n/a	n/a	May 12, 2017
Madhu Kumar Chardan Capital	Chardan Capital	Strong Sell Reiterates $100 → $130	Strong Sell	Reiterates	$100 → $130	+49,900.00%	Apr 17, 2017
Madhu Kumar Chardan Capital	Chardan Capital	Strong Sell Initiates $100	Strong Sell	Initiates	$100	+38,361.54%	Jul 11, 2016